Biopharmaceuticals Company Profile News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biopharmaceuticals company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biopharmaceuticals Company Profile Today - Breaking & Trending Today

Euclidean Capital LLC Purchases 245,494 Shares of NGM Biopharmaceuticals, Inc. (NASDAQ:NGM)

Euclidean Capital LLC Purchases 245,494 Shares of NGM Biopharmaceuticals, Inc. (NASDAQ:NGM)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Raymond James , Biopharmaceuticals Inc , Prelude Capital Management , Hong Kong Ltd , Biopharmaceuticals Company Profile , Tower Research Capital , Euclidean Capital , Free Report , Capital Management , Research Capital , Kong Ltd , Fire Capital , Virginia Retirement Systems , Stock Down ,

NGM Biopharmaceuticals' (NGM) "Neutral" Rating Reaffirmed at Citigroup

NGM Biopharmaceuticals' (NGM) "Neutral" Rating Reaffirmed at Citigroup
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Hong Kong , Prelude Capital Management , Biopharmaceuticals Company Profile , Biopharmaceuticals Inc , Royal Bank , Hong Kong Ltd , Tower Research Capital , Get Free Report , Trading Down , Kong Ltd , Research Capital ,

NGM Biopharmaceuticals (NASDAQ:NGM) Price Target Cut to $3.50 by Analysts at B. Riley

NGM Biopharmaceuticals (NASDAQ:NGM – Free Report) had its target price reduced by B. Riley from $7.00 to $3.50 in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. NGM Biopharmaceuticals Price Performance NASDAQ:NGM opened at $0.76 on Wednesday. The firm has a market cap […] ....

Biopharmaceuticals Company Profile , Blackrock Inc , Acadian Asset Management , Vanguard Group Inc , Biopharmaceuticals Inc , Free Report , Get Free Report , Asset Management , Ngm Biopharmaceuticals , Nasdaq Ngm , Lower Price Target , B Riley ,

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Receives Average Rating of "Moderate Buy" from Analysts

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among […] ....

United States , Hong Kong , Biopharmaceuticals Company Profile , Biopharmaceuticals Inc , Ngm Biopharmaceuticals Inc , Mackenzie Financial Corp , Hong Kong Ltd , Royal Bank , Get Free Report , Marketbeat Ratings , Kong Ltd , Retirement System , State Retirement System , Get Free , Ngm Biopharmaceuticals , Nasdaq Ngm ,

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Receives Consensus Recommendation of "Moderate Buy" from Analysts

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) has earned an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokers […] ....

Ameriprise Financial Inc , Biopharmaceuticals Inc , Biopharmaceuticals Company Profile , Geode Capital Management , Putnam Investments , Ngm Biopharmaceuticals Inc , Get Rating , Trading Down , Street Group , Street Corp , Capital Management ,